Metformin Linked to Increased Risk of Acute Dialysis in T2DM
Metformin Linked to Increased Risk of Acute Dialysis in T2DM

Metformin-associated one-year risk of acute dialysis increased by 50.3 per 100,000 individuals

TUESDAY, Aug. 23, 2016 (HealthDay News) — For patients with type 2 diabetes, metformin is associated with about a 50 percent increase in the risk of acute dialysis compared to sulfonylureas, according to a study published online Aug. 18 in Diabetes, Obesity and Metabolism.

Nicholas Carlson, M.D., from Copenhagen University in Denmark, and colleagues conducted a retrospective nationwide cohort study involving 168,443 drug-naive patients with type 2 diabetes aged 50 years and older. Participants initiated treatment with metformin or sulfonylurea between 2000 and 2012 (70.7 percent initiated treatment with metformin).

The researchers found that the one-year risk for acute dialysis was 92.4 per 100,000 for sulfonylurea and 142.7 per 100,000 for metformin. The one-year risk of acute dialysis associated with metformin was increased by 50.3 per 100,000 (risk ratio, 1.53; number needed to harm, 1,988).

“In a retrospective nationwide cohort study on the risk of acute dialysis associated with initiation of metformin in patients with type 2 diabetes, treatment with metformin was associated with a 50 percent increase in risk of acute dialysis compared with sulfonylurea,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this article
Share on facebook
Share on twitter
Share on linkedin
Your must go through these
View More Related Blogs
0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Upload Test Report Form

    Any Query?